Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B. subtilis-cNK-2
- Development stage
- Preclinical
- Lead developer
- US Biologic
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Peptides, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
B. subtilis-cNK-2 is an oral vaccine and antibiotic alternative being developed by US Biologic in collaboration with the USDA Agricultural Research Service for the prevention and treatment of poultry coccidiosis. The therapeutic utilizes the OrisBio platform, which employs recombinant *Bacillus subtilis* spores engineered to express chicken NK-lysin peptide 2 (cNK-2), a host-derived antimicrobial peptide. The mechanism of action involves the direct disruption of the *Eimeria* sporozoite membrane during the invasive stage of the parasite's life cycle, leading to cytotoxic effects. Additionally, the treatment modulates local inflammatory responses, enhances gut integrity, and stabilizes the gut microbiota in broiler chickens. Preclinical studies have demonstrated that oral administration significantly reduces fecal oocyst shedding and improves growth performance, positioning it as a potential replacement for traditional ionophores and chemical coccidiostats in commercial poultry production.
- Other names
- Oral Anti-Coccidiosis TreatmentBacillus subtilis-cNK-2
02
Targets
Parasitic membrane of Eimeria spp.
Beyond the preview
Go deeper on B. subtilis-cNK-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B. subtilis-cNK-2.